Ex Vivo Normothermic Perfusion in Kidney Transplantation.

Inclusion Criteria: 1. Patients aged 18 years and older 2. Patients undergoing renal replacement therapy by means of dialysis and included in the waiting list for renal transplantation in their respective site. 3. Candidates to receive a first or second renal transplant from (i) a Maastricht type III (Maastricht classification) controlled DCD donor or (ii) a DBD donor aged 70 years or older. 4. Patients that have given informed consent in written form before their inclusion in the study. In case of compromised mental capacity, the approval and signature of a legal guardian will be required. 5. Patients compliant with the requirements of the study and without impediments to follow the instructions throughout the 1-year duration of the study. 6. Patients that meet the acceptance criteria for kidney transplant recipients established in the clinical site in agreement with usual clinical practice. Exclusion Criteria: 1. Two or more previous kidney transplantations 2. Dual kidney transplantation or multivisceral transplantation (e.g. a pancreas-kidney transplantation) 3. Recipients of an organ with any of the following characteristics: 1. Expected cold ischemia time before EVNP \> 20 hours 2. Organ from hepatitis B surface antigen-positive or hepatitis C viremic donor 3. Organ with multiple arteries 4. Recipients with body mass index (BMI) \> 40 kg/m2 5. Diagnosis of focal segmental glomerulosclerosis (FSGS) or membranoproliferative glomerulonephritis with high recurrence risk after transplantation in the eyes of the investigator. 6. Diagnosis of atypical hemolytic-uremic syndrome or thrombotic microangiopathy at the moment of inclusion 7. Diagnosis of antiphospholipid syndrome at the moment of inclusion 8. Panel-reactive antibodies (PRA) score \> 50% 9. Known allergies to any of the components of the perfusate 10. Preexisting vascular disease that represents an extraordinary technical difficulty for the transplantation in the opinion of the investigator 11. Presence of clinically relevant donor-specific anti-HLA antibodies 12. ABO incompatibility 13. History of alcohol or drug abuse in the last two years 14. Use of normothermic regional perfusion during the organ harvesting process 15. Participation of the patient in another study or clinical trial.